Financial Results | Sanofi 2025 Half-Year Revenue EUR 21341.00 Million Net Income EUR 5837.00 Million

Sanofi(SNY) posted the Q2 of its 2025 financial results on 7/31/2025, reporting total revenue of EUR 21341.00 million in the first half of the year, up 7.30% from EUR 19889.00 million year over year, reporting net income of EUR 5837.00 million in the first half of the year, up 157.93% from EUR 2263.00 million year over year. The EPS is EUR 4.74 in the first half of the year, compare with EUR 1.8 last period.

[Detailed Data]

Million EUR	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Total Revenue	10735.00	10606.00	11420.00	14157.00
Cost of Sales	2993.00	2889.00	3576.00	4085.00
Gross Profit	7742.00	7717.00	7844.00	10072.00
Total Operating Expenses	6319.00	5559.00	6783.00	6569.00
Operating Income	1423.00	2158.00	1061.00	3503.00
Net Income	3943.00	1893.00	695.00	2844.00
Net Income Attributable to Common Shareholders	3939.00	1872.00	683.00	2815.00
EPS(EUR)	3.24	1.52	0.54	2.25

[Company Profile]
Sanofi was incorporated under the laws of France in 1994. The company is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company's activities are organized around the following categories: DUPIXENT, Neurology & Immunology, Rare Diseases, Oncology, Rare Blood Disorders, General Medicines Core Assets and Non-Core Assets, Vaccines, and CHC.